Filtered By:
Condition: Heart Valve Disease

This page shows you your search results in order of date. This is page number 18.

Order by Relevance | Date

Total 554 results found since Jan 2013.

Current status and future perspective of structural heart disease intervention.
Abstract Valvular heart diseases are one of the most frequent causes for heart failure. Degenerative diseases of the aortic and mitral valve as well as a dysfunctional tricuspid valve disease result in a worse clinical outcome if severe. Minimal-invasive, surgical and/or catheter-based structural heart disease (SHD) interventions have recently seen a dramatic increase. Transcatheter aortic valve implantation (TAVI) for severe aortic stenosis (AS) is a disruptive technology, and next generation devices and careful patient selection will minimize limitations of TAVI such as paravalvular leak, conductance disturbance...
Source: Journal of Cardiology - April 3, 2019 Category: Cardiology Authors: Tabata N, Sinning JM, Kaikita K, Tsujita K, Nickenig G, Werner N Tags: J Cardiol Source Type: research

Anticoagulation of Cardiovascular Conditions in the Cancer Patient: Review of Old and New Therapies
AbstractPurpose of ReviewThe anticoagulation strategies for various cardiac-specific pathologies including atrial fibrillation are changing. Applying these strategies in patients with concomitant active cancer requires additional considerations. Here, we review the most recent changes in the anticoagulation management of common cardiac diseases and their application in cancer patients.Recent FindingsThere are a range of indications for therapeutic anticoagulation in cancer patients including venous thromboembolism (VTE), atrial fibrillation/flutter (AF/AFL), prosthetic heart valves, and intracardiac thrombi. Certain cancer...
Source: Current Oncology Reports - April 3, 2019 Category: Cancer & Oncology Source Type: research

Prognostic significance of preoperative ECG Strain after Transcatheter Aortic Valve Replacement for severe Aortic Stenosis
ConclusionPreoperative ECG Strain was associated with higher risk of ME onset after TAVR for severe AS.
Source: Archives of Cardiovascular Diseases Supplements - March 22, 2019 Category: Cardiology Source Type: research

ACC 2019: Medtronic, Edwards low-risk TAVR trial data could pave way to new indications
Results from trials of both Medtronic‘s (NYSE:MDT) and Edwards Lifesciences‘ (NYSE:EW) transcatheter aortic valve replacement systems exploring their use in low-risk patients indicated that the devices were as safe as open surgery, paving the way for possible new indications for TAVR technology. Data from the trials were presented over the weekend at the American College of Cardiology 68th Annual Scientific Session 2019 in New Orleans and simultaneously published in the New England Journal of Medicine. Currently, TAVR devices are only approved by the FDA for treating severe aortic valve stenosis in patients at inte...
Source: Mass Device - March 18, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Featured Replacement Heart Valves Edwards Lifesciences Medtronic Source Type: news

Whipple's endocarditis diagnosed by thrombus analysis retrieved by successful mechanical thrombectomy
We report a case of Whipple Endocarditis leading to a proximal embolic stroke successfully treated by mechanical thrombectomy.
Source: Journal of the Neurological Sciences - March 13, 2019 Category: Neurology Authors: Ong Elodie, Paul-Emile Labeyrie, Matthieu Aubry, Delahaye Cecile, Sandrine Roux, Tristan Ferry, Norbert Nighoghossian Tags: Letter to the Editor Source Type: research

Study of Boston Scientific ’s Lotus, Medtronic’s CoreValve shows similar outcomes at 2 years
Two-year results from a head-to-head study comparing transcatheter aortic heart valve replacement devices from both Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT) indicated similar outcomes for the competing products. The study, published recently in the journal JAMA Cardiology, compared Marlborough, Mass.-based Boston Scientific’s Lotus valve to Fridley, Minn.-based Medtronic’s CoreValve system. Investigators in the study compared outcomes for 912 patients with high or extreme risk and severe, symptomatic aortic stenosis after treatment with one of the two devices. Patients, treated between September 22, 2014...
Source: Mass Device - February 28, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials Featured Replacement Heart Valves Boston Scientific Medtronic Source Type: news

Non-vitamin K antagonist oral anticoagulants (NOACs) in the treatment of coronary and peripheral atherosclerosis. Expert Consensus.
Abstract Oral anticoagulants (OAC) are widely used for prevention of systemic thromboembolism, including the reduction of the risk of stroke in patients with atrial fibrillation (AF) and prosthetic heart valves. There is also an increasing population of patients who require not only OACs, but also double antiplatelet therapy (DAPT). A typical example is a patient with AF and stable coronary artery disease or acute coronary syndrome (ACS), treated by percutaneous coronary intervention (PCI). In recent years, with the introduction of NOACs, triple or dual therapy has become safer. Regardless of these indications for...
Source: Polish Heart Journal - February 25, 2019 Category: Cardiology Authors: Witkowski A, Barylski M, Filipiak KJ, Gierlotka M, Legutko J, Lesiak M, Stępińska J, Wojakowski W Tags: Kardiol Pol Source Type: research

Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation
ConclusionsMorbidly obese AF patients treated with rivaroxaban had comparable risk of ischemic stroke/systemic embolism and major bleeding as those treated with warfarin, but lower healthcare resource utilization and costs.
Source: American Heart Journal - February 21, 2019 Category: Cardiology Source Type: research

Scientists discover new type of immune cells that are essential for forming heart valves
UCLA researchers have identified for the first time the origin of an immune cell that plays a critical role in the formation of healthy heart valves. The findings could pave the way for new treatments for heart valve disorders, which can be caused by congenital defects, aging or disease.Their study, led by Dr. Atsushi “Austin” Nakano, a UCLA associate professor of molecular, cell and developmental biology and member of theEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, was published in the journal Developmental Cell.Building on previous research by Nakano, which showed that the embr...
Source: UCLA Newsroom: Health Sciences - February 21, 2019 Category: Universities & Medical Training Source Type: news

Opioid epidemic fueling a rise in infection-related stroke
(American Heart Association) The opioid epidemic is fueling a steep rise in infection-related stroke hospitalizations. Injecting opioids, such as heroin, can introduce bacteria into the body which travels through the bloodstream to infect heart valves. Clumps of infected tissue can break off and travel to the brain, resulting in stroke.
Source: EurekAlert! - Medicine and Health - January 30, 2019 Category: International Medicine & Public Health Source Type: news

Oral Anticoagulation.
CONCLUSION: The evidence base for anticoagulation over a time frame of several years is inadequate at present, and direct comparative data for the different types of NOAC are not yet available. PMID: 30602410 [PubMed - in process]
Source: Deutsches Arzteblatt International - January 5, 2019 Category: General Medicine Tags: Dtsch Arztebl Int Source Type: research

Thromboembolic and bleeding risk stratification according to the EHRA valvular heart disease classification in patients with atrial fibrillation
ConclusionThis systematic analysis in real life conditions shows that distinguishing AF patients according to the new EHRA valve classification could be relevant for creating more homogenous groups of patients in terms of TE and bleeding risk. This clearer classification than the previous one should be useful as in clinical research for harmonization of studies, as well as in clinical practice for targeted choices of OAC therapy.
Source: Archives of Cardiovascular Diseases Supplements - December 25, 2018 Category: Cardiology Source Type: research

Treatment of Simultaneous Thromboembolism of the Right and Left Coronary Arteries with Thrombus Aspiration in a Patient with a Prosthetic Mitral Valve.
Authors: Sığırcı S, Keskin K, Sezai Yıldız S, Aksan G, Bambul Sığırcı B, Orta Kılıçkesmez K Abstract Prosthetic heart valve thrombosis is a rare, difficult-to-treat condition that increases morbidity and mortality by leading to systemic embolism. Clinically, it presents mainly in the form of stroke, though an embolism be observed in many systems. Acute coronary syndrome, which is rarely observed in patients with a prosthetic heart valve, mostly occurs as non-ST segment elevation myocardial infarction (MI). There is no specific recommendation for the treatment of this condition. Revascularization succes...
Source: Journal of Heart Valve Disease - December 19, 2018 Category: Cardiology Tags: J Heart Valve Dis Source Type: research

Early Hemodynamic Performance of the Crown PRT Aortic Prosthesis: A Prospective Study.
CONCLUSIONS: The Crown PRT is an effective bioprosthesis, with a low incidence of valve-related complications comparable to those of other current bioprostheses. The bioprosthesis demonstrated satisfactory results in terms of hemodynamics and freedom from reoperation. PMID: 30560604 [PubMed - in process]
Source: Journal of Heart Valve Disease - December 19, 2018 Category: Cardiology Tags: J Heart Valve Dis Source Type: research

Evolution of Veterans Affairs Transcatheter Aortic Valve Replacement Program: The First 100 Patients.
CONCLUSIONS: Successful outcomes were demonstrated for a VA TAVR program that compared favorably with benchmarks established by the National Transcatheter Valve Therapies Registry. These results provide a necessary transparency of TAVR outcomes at a federal institution. PMID: 30560596 [PubMed - in process]
Source: Journal of Heart Valve Disease - December 19, 2018 Category: Cardiology Tags: J Heart Valve Dis Source Type: research